Michael B Battles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4943513/publications.pdf

Version: 2024-02-01

759055 1125617 1,061 13 12 13 citations h-index g-index papers 14 14 14 2472 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	6.0	285
2	Respiratory syncytial virus entry and how to block it. Nature Reviews Microbiology, 2019, 17, 233-245.	13.6	187
3	Five birds, one stone: Neutralization of α-hemolysin and 4 bi-component leukocidins of <i>Staphylococcus aureus</i> with a single human monoclonal antibody. MAbs, 2015, 7, 243-254.	2.6	125
4	Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology, 2016, 12, 87-93.	3.9	121
5	Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nature Communications, 2017, 8, 1528.	5.8	86
6	Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nature Communications, 2017, 8, 167.	5.8	58
7	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications, 2017, 8, 1877.	5.8	53
8	Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of <i>Staphylococcus aureus </i> for the generation of neutralizing antibodies. MAbs, 2016, 8, 1347-1360.	2.6	44
9	Alternative conformations of a major antigenic site on RSV F. PLoS Pathogens, 2019, 15, e1007944.	2.1	29
10	A color-based stable multi-copy integrant selection system for Pichia pastorisusing the attenuated ADE1 and ADE2 genes as auxotrophic markers. Bioengineered, 2012, 3, 32-37.	1.4	17
11	NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors. Molecular Cancer Therapeutics, 2017, 16, 1335-1346.	1.9	17
12	Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1 <i>H</i> -indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2 <i>H</i> (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus. Journal of Medicinal Chemistry, 2020, 63, 8046-8058.	<td>zo[45-<i>c</i></td>	zo[45- <i>c</i>
13	Directed Evolution of a Yeast-Displayed HIV-1 SOSIP gp140 Spike Protein toward Improved Expression and Affinity for Conformational Antibodies. PLoS ONE, 2015, 10, e0117227.	1.1	8